Apr 25, 2023 · While Novo Nordisk is probably the better weight-management stock, a more diverse product lineup and development pipeline make Eli Lilly the better overall pharmaceutical business.

Aug 3, 2024 · Eli Lilly (LLY 2.45%) and Novo Nordisk (NVO 8.47%) are the two big names dominating the anti-obesity market today. They've been generating billions in revenue from their treatments, and...

Mar 27, 2024 · Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro and Zepbound—brand names for semaglutide and tirzepatide—are undisputed leaders among the class of GLP-1 hormone-mimicking drugs used to treat...

Dec 30, 2024 · While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short of a staggering financial success, the rollouts have consistently been hamstrung by manufacturing ...

Mar 25, 2024 · Novo Nordisk and Eli Lilly manufacture the primary medications used to treat obesity care and diabetes. But a small biotech company just announced positive results from a phase 2...

Jan 31, 2024 · Norway's giant wealth fund says Novo Nordisk and Eli Lilly could be on course to become the first health care companies to join the trillion-dollar club.

Mar 25, 2024 · Novo Nordisk and Eli Lilly dominate the weight-loss market, but progress from a rising biotech could spell trouble for the pharma giants.

Nov 2, 2023 · On Thursday, Novo Nordisk, the Denmark-based company behind Ozempic and Wegovy, reported a 29% increase in sales to $8.4 billion for the third quarter. Eli Lilly, which makes diabetes drug...

Jan 6, 2025 · Novo Nordisk (NVO) and Eli Lilly (NYSE: LLY) dominate this market, and in this article I will shed light on what is happening in this regard and how the market for weight-loss drugs may...

May 15, 2024 · The mass interest in GLP-1 drugs has led to a business boom for the two dominant pharmaceutical players in this space, Lilly and Novo Nordisk, which sold over $7.3 billion worth of its GLP-1...